Kalamazoo, Michigan – April 27, 2011 – Stryker Corporation (NYSE: SYK) today announced that former Johnson & Johnson executive Kevin Lobo was appointed as a group president to lead the newly formed Neurotechnology and Spine Group. Lobo joins Stryker after nearly a decade at Johnson & Johnson, where he held a number of senior-level leadership roles, most recently as worldwide president of Ethicon Endo-Surgery, a $4 billion division with more than 5,000 employees. These moves follow Stryker’s January 3, 2011, closing of the acquisition of Boston Scientific’s Neurovascular division, which broadened the Company’s existing presence in the neurosurgery space. The new group includes Stryker’s Neurovascular and Spine divisions.
“The creation of our new Neurotechnology and Spine Group will enable us to bring stronger alignment to these exciting market segments, and better serve the evolving needs of our surgeon customers in these innovative areas,” said Stephen P. MacMillan, Chairman, President and Chief Executive Officer of Stryker Corporation. “Kevin’s record of delivering business results, his strong customer focus and his global leadership abilities are ideally suited for ensuring we capitalize on the many opportunities the neurotechnology and spine markets present our organization.”
Stryker is one of the world’s leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.
Katherine A. Owen
Vice President, Strategy and Investor Relations